Theravance Biopharma Investor Relations Material
Latest events
Q2 2024
Theravance Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Theravance Biopharma Inc
Access all reports
Theravance Biopharma Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of respiratory and organ-selective medicines. The company's primary product is YUPELRI (revefenacin), a once-daily nebulized therapy used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Theravance Biopharma is also involved in the development of Ampreloxetine, an investigational norepinephrine reuptake inhibitor, targeting neurogenic orthostatic hypotension, and has collaborations for additional research in respiratory and immunological disorders. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Theravance Biopharma Inc
Q2 2024
Theravance Biopharma Inc
Q2 2024
Theravance Biopharma Inc
Latest articles
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
Ticker symbol
TBPH
Country
🇺🇸 United States